1. Antibody–drug conjugates (ADCs)—new targeted therapies

   • Georgios Papakonstantinou

   editorial 26 November 2013 Pages: 223 - 224

2. Neurooncology: current findings and challenges for the future

   • Silvia Hofer

   editorial 22 June 2013 Pages: 225 - 226

3. ASCO 2013: news in early-stage and advanced breast cancer

   • Günther G. Steger
   • Rupert Bartsch

   short review 26 November 2013 Pages: 227 - 232

4. Recent developments in the palliative treatment of breast cancer: ASCO 2013

   • Edgar Petru
   • Tina Idris
   • Eva Schest

   special report 29 October 2013 Pages: 233 - 235

5. ASCO 2013: new developments in lung cancer

   • Andreas Pircher
   • Michael Fiegl
   • Wolfgang Hilbe

   short review 26 November 2013 Pages: 236 - 239

6. ASCO annual meeting 2013: head and neck cancer

   • Georg Pall

   short review 21 September 2013 Pages: 240 - 243

7. ASCO 2013—treatment of metastatic melanoma: is it still a story of success?

   • Georg Weinlich

   short review 23 October 2013 Pages: 244 - 246

8. Update on neurooncology Annual meeting of the American Society of Clinical Oncology (ASCO) 2013

   • Silvia Hofer
   • Christine Marosi

   short review 25 September 2013 Pages: 247 - 250

9. ASCO 2013—new concepts and the path to individualized therapy

   • Heinz Zwierzina

   comment 10 December 2013 Pages: 251 - 253

10. Transfusion-associated graft-versus-host disease: an update

    • Christian Dal-Pont
    • Harald Schennach

    short review 23 October 2013 Pages: 254 - 257

11. The contribution of antibodies to targeted cancer therapy

    • Panagiotis Apostolou
    • Ioannis Papasotiriou

    short review 28 November 2013 Pages: 258 - 261

12. Targeted delivery of anticancer agents using antibodies as vectors

    • Maria Toloudi
    • Ioannis Papasotiriou

    short review 29 November 2013 Pages: 262 - 266

    

13. T-DM1 in breast cancer therapeutics: the first drug of its generation

    • Michalis V Karamouzis

    review 23 October 2013 Pages: 267 - 270

14. Targeting AML with anti-CD33 antibodies: historical walkthrough, clinical impact, future directions

    • Spyridon Dimitrios Chondropoulos
    • Annaliza Delastic
    • Alexandros Spyridonidis

    short review 10 December 2013 Pages: 271 - 274

    

15. Brentuximab vedotin, a highly active ADC as a new therapeutic option for CD30+ lymphomas

    • Sofia Stamatopoulou

    short review 12 December 2013 Pages: 275 - 277